Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.American journal of epidemiology · 2017
   Pooled it
2. Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.Future oncology (London, England) · 2014
   Pooled it
3. ClinicalCancers · 2021
   Review
4. CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.Breast cancer research : BCR · 2018
   Article
5. Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People.Clinical and translational science · 2018
   Article
6. Breast cancer recurrence in relation to antidepressant use.Cancer causes & control : CCC · 2016
   Article
7. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.Journal of the National Cancer Institute · 2014
   Article
8. 'Toxgnostics': an unmet need in cancer medicine.Nature reviews. Cancer · 2014
   Review
9. Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.Journal of the National Cancer Institute · 2014
   Article
10. Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer.British journal of clinical pharmacology · 2014
    Article
11. Status of adjuvant endocrine therapy for breast cancer.Breast cancer research : BCR · 2014
    Review
12. Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.Journal of the National Cancer Institute · 2013
    Article
13. Pharmacogenomics of breast cancer therapy: an update.Pharmacology & therapeutics · 2013
    Review
14. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013
    Article
15. Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study.International journal of molecular epidemiology and genetics · 2013
    Article
16. Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010.Breast cancer research and treatment · 2013
    Article

Corrections and comments

• Comment on
  CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.2012
• Comment on
  CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.2012
• Comment on
  CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.2012

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as